HMGB1 and neoplasm: Some studies demonstrated that certain chemotherapeutic agents (e.g., DOX) could induce ICD, release tumor antigens as well as high mobility group box 1 (HMGB1), and then recruit and activate antigen-specific immune cells eliciting personalized antitumor immune responses at local tumor tissue, which was also named in situ vaccine [7, 8].